新型AT拮抗剂──替米沙坦

A NEW AT-ANTAGONIST──TELMISARTAN

替米沙坦是一种非肽类血管紧张素Ⅱ受体拮抗剂，可选择性、难以逆转的阻滞AT1受体，而对其他受体，尤其是心血管系统的受体无影响。与安慰剂相比，给予Ⅰ－Ⅱ期高血压患者40—160mg／次，qd给药时，可显著降低收缩压和舒张压，其疗效至少与阿替洛尔50，100mg或赖诺普利10－40mg相当。本品耐受性良好。

Telmisartan, a nonpeptide angiotensin Ⅱ receptor antagonist, selectively and unconvertiblely inhibits AT1 receptor without action on other receptors especially those in cardiovascular system. Its efficacy, tolerability, and clinical uses were reviewed.